Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ...

Area of Science:

• Immunology
• Cancer Biology
• Biochemistry

Background:

• Protein-tyrosine phosphatases (PTPs), specifically PTP1B and TC-PTP, are key regulators of the JAK/STAT signaling pathway.
• This pathway is crucial for cytokine-receptor activation in immune cells, particularly dendritic cells (DCs).

Purpose of the Study:

• To explore a novel immunotherapy strategy by enhancing monocyte-derived dendritic cell (moDC) function through modulation of PTP1B and TC-PTP enzymatic activities.
• To investigate the effects of PTP downregulation or deletion on DC immunogenicity and therapeutic potential in cancer.

Main Methods:

• Generation of mice with specific PTP deletions in the dendritic cell compartment.
• Utilizing specific inhibitors for PTP1B and TC-PTP.
• Assessing DC phenotype, cytokine production (IL-12, IFNγ), and STAT/Src kinase activation.
• Evaluating the therapeutic efficacy of moDCs in tumor-bearing mice and in vitro from pancreatic cancer patients.

Main Results:

• Total ablation of PTP1B or TC-PTP resulted in tolerogenic DCs due to STAT3 hyperactivation.
• Downregulation of PTP1B or TC-PTP promoted an immunogenic DC phenotype via STAT4, STAT1, and Src kinase hyperactivation.
• This shift increased IL-12 and IFNγ production, amplifying an autocrine loop and enhancing DC therapeutic potential in tumor models.
• Pharmacological inhibition of both PTPs improved the maturation of defective moDCs from pancreatic cancer patients.

Conclusions:

• Modulating PTP1B and TC-PTP activity represents a promising strategy for enhancing DC-based cancer immunotherapy.
• This approach can convert tolerogenic DCs into immunogenic ones, amplifying anti-tumor immune responses.
• The findings offer a complementary therapeutic avenue for pancreatic cancer and other malignancies.